ABSTRACT BACKGROUND Left atrial appendage closure (LAAC) and nonwarfarin oral anticoagulants (NOACs) have emerged as
More recently, 4 nonwarfarin oral anticoagulants (NOACs) (dabigatran, rivaroxaban, apixaban, and edoxaban) were approved by the U.S. Food and Drug Administration (FDA). As a group, they are noninferior to warfarin for ischemic stroke reduction and superior for hemorrhagic stroke and all-cause mortality, but they have an increased risk for gastrointestinal bleeding (4) . As with warfarin, the effectiveness of these drugs is contingent on patient adherence.
For patients who are poor candidates for long-term oral anticoagulation, percutaneous left atrial appendage closure (LAAC) is a device-based alternative for stroke prophylaxis in AF (5) . The first FDA-approved LAAC device, the Watchman device (Boston Scientific, Marlborough, Massachusetts), was demonstrated to be noninferior to warfarin for ischemic stroke reduction and superior for hemorrhagic stroke and all-cause mortality. However, it is associated with procedure-related complications that predictably diminish in frequency with operator experience (6) . Importantly, most patients can discontinue lifelong anticoagulation following Watchman device implantation (6) . 
Time to Cost-Effectiveness Following AF Treatment derived baseline risks. For warfarin, the relative risk of stroke was derived from a meta-analysis of warfarin trials (10) . Risk data for all other warfarin-related clinical events were estimated from a pooled analysis of multiple AF clinical trials involving warfarin (4, (16) (17) (18) (19) (20) . NOAC clinical event rates were derived from a NOAC meta-analysis and from individual NOAC trials (4,12,13,21,22). Reddy et al.
Time to Cost-Effectiveness Following AF Treatment
Probabilities of death following systemic embolism, extracranial hemorrhage, or myocardial infarction were derived from Healthcare Utilization Project mortality rates for these diagnoses (23 scores (11, 26) . Because neither measure was prospectively collected in the PROTECT AF or NOAC trials, both were estimated using available baseline Values are relative risks or risk percentages. *RR of post-procedural ischemic stroke (relative to warfarin) uses a range of AE20% as the published 95% CI includes risk of intraprocedure stroke. †Denotes 95% CI.
BAAFT ¼ Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA ¼ Canadian Atrial Fibrillation Anticoagulation; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, stroke-vascular disease; CI ¼ confidence interval; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (>65 years), drugs/alcohol concomitantly; LAAC ¼ left atrial appendage closure; NOAC ¼ nonwarfarin oral anticoagulant; RR ¼ relative risk; SPAF 1 ¼ Stroke Prevention in Atrial Fibrillation; SPINAF ¼ Stroke Prevention in Nonrheumatic Atrial Fibrillation.
characteristic data from the trials. Patients were assumed to be 70 years of age, with a mean CHA 2 DS 2 -VASc score of 3.2 (annual stroke risk 3.4%), and a HAS-BLED score of 2 (annual bleeding risk 1.88%) (11, 26) . To account for increasing risk with age, rates of ischemic and hemorrhagic stroke were increased by 1.4-and 1.97-fold per decade, respectively (27, 28) .
Patients experiencing a TIA or systemic embolism were assumed to have a 2.6-fold higher risk of experiencing a second ischemic event (28) .
HEALTH STATE UTILITIES AND STROKE OUTCOMES.
As is conventional in cost-effectiveness analyses, QoL Because stroke is the most debilitating consequence of AF, QoL also was assessed by stroke severity. Stroke outcomes were assigned using the modified Rankin score (MRS) and were characterized as nondisabling (MRS 0 to 2), moderately disabling (MRS 3), severely disabling (MRS 4 to 5), and fatal (MRS 6) ( Table 2) . Stroke outcomes for LAAC were gathered from additional analyses of PROTECT AF at 4 years. Warfarin stroke outcomes were estimated using a weighted average of outcomes from 4 warfarin trials (16, 17, 19, 20) . NOAC stroke outcomes were derived from 2 of the 4 pivotal trials (12, 13) . Because only the rate of nondisabling strokes was reported, the inverse represented disabling and fatal strokes, with the distribution of moderately disabling, severely disabling, and fatal strokes assumed to be the same as with warfarin.
Additionally, a series of disutilities was applied in the model for acute clinical events, representing a 1-time decrement to QoL experienced for a finite length of time. Utility decrements were assessed for stroke (À0.139), extracranial hemorrhage (À0.181), TIA (À0.103), systemic embolism (À0.120), and myocardial infarction (À0.125) (36) . A value of À0.0315 was used for the LAAC procedure itself, which assumed a 2-week disruption to healthy life.
QALYs were calculated by multiplying the health state utility value of each health state by the mean time spent in the health state. Future QALYs were discounted at an annual rate of 3% (37) .
COSTS.
The model incorporated all direct health care costs for the therapies and treatment of associated acute events, as well as costs for long-term care following a disabling stroke ( Table 3) . Costs Reddy et al. Table 1 . Reddy et al. HS ¼ hemorrhagic stroke; ICH ¼ intracranial hemorrhage; IS ¼ ischemic stroke. there was a 94% probability that LAAC was cost saving relative to warfarin, a 97% probability that LAAC provided more QALYs, and a 100% probability that it provided more life-years. The overall probability of cost-effectiveness was 98%, using a willingness-to-pay threshold of $50,000/QALY. At 20 years, there was a 95% probability that LAAC was cost-effective relative to NOACs and a 75%
probability that NOACs were cost-effective relative to warfarin. Similar outcomes, albeit with greater scatter, are seen when the PSAs were conducted at 10 years (Online Figures 3A to 3C) . Time
